Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit
cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at
opm.gov.
Safety, Efficacy, and Cost-Effectiveness of Rituximab for Multicentric Castleman Disease in Malawi
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
International Research Scientist Development Award (IRSDA)
Project Information in NIH RePORTER
Safety, Efficacy, and Cost-Effectiveness of Rituximab for Multicentric Castleman Disease in Malawi
Principal Institution
University of North Carolina Chapel Hill
Principal Investigator(s) (PI)
Painschab, Matthew Scott
Project Contact Information
Email:
mpain@email.unc.edu
Year(s) Awarded
2019-2024
Country
Malawi
Collaborators
UNC Project Malawi
Kamuzu Central Hospital
Project Description
Multicentric Castleman disease (MCD) is a life-threatening lymphoproliferative disorder (in which cells of the lymphatic system grow excessively) strongly associated with Kaposi sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV), which are both highly prevalent in sub-Saharan Africa. Treatment with chemotherapy can control the disease but rapid relapses occur and mortality is high when chemotherapy is stopped. Rituximab, however, has been effective in small studies in high-income countries to control MCD and decrease mortality. Rituximab has not been formally evaluated in sub-Saharan Africa however. We will therefore conduct a phase II safety/efficacy trial of rituximab-based therapy for MCD in Malawi, a low-income country in sub-Saharan Africa, where MCD constitutes an important HIV co-morbidity.
Related World Regions / Countries
Related Global Health Research Topics